Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DapaHeart: Effect of dapagliflozin on myocardial insulin sensitivity and perfusion
2016-003614-27Phase 4Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Policlinico Gemelli. Primary endpoint: myocardial glucose uptake. Started Feb 2018; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-003614-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003614-27.